|
[1]NG SC,SHI HY,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studyies[J].Lancet,2018,390(10114):2769-2778．
|
|
[2]ANIWAN S,PARK SH,LOFTUS EV Jr.Epidemiology,natural history,and risk stratification of Crohn's disease[J].Gastroenterol Clin North Am,2017,46(3):464-480．
|
|
[3]BOUMA G,STROBER W.The immunological and genetic basis of inflammatory bowel disease[J].Nat Rev Immunol,2003,7(3):521-533．
|
|
[4]CHAPMAN MH,THORBURN D,HIRSCHFIELD GM,et al.British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis[J].Gut,2019,68(8):1356-1378．
|
|
[5]RUST C,BRAND S.PSC:Protect and serve with colitis:Does it help the liver to have severe ulcerative colitis?[J].Gut,2011,60(9):1165-1166．
|
|
[6]CHAPMAN RW,ARBORGH BA,RHODES JM,et al.Primary sclerosing cholangitis:A review of its clinical features,cholangiography,and hepatic histology[J].Gut,1980,21(10):870-877．
|
|
[7]OLIVEIRA LC,PORTA G,MARIN ML,et al.Autoimmune hepatitis,HLA and extended haplotypes[J].Autoimmun Rev,2011,10(4):189-193．
|
|
[8]LIU JZ,HOV JR,FOLSERAAS T,et al.Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis[J].Nat Genet,2013,45(6):670-675．
|
|
[9]CARIO E,BROWN D,MCKEE M,et al.Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium[J].Am J Pathol,2002,160(1):165-173．
|
|
[10]HIRSCHFIELD GM,KARLSEN TH,LINDOR KD,et al.Primary sclerosing cholangitis[J].Lancet,2013,382(9904):1587-1599．
|
|
[11]DAWSON PA,KARPEN SJ.Intestinal transport and metabolism of bile acids[J].J Lipid Res,2015,56(6):1085-1099．
|
|
[12]DAWSON PA.Toxic bile and sclerosing cholangitis:Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?[J].Hepatology,2016,63(2):363-364．
|
|
[13]WILLIAMSON KD,CHAPMAN RW.New therapeutic strategies for primary sclerosing cholangitis[J].Semin Liver Dis,2016,36(1):5-14．
|
|
[14]TABIBIAN JH,VARGHESE C,LARUSSO NF,et al.The enteric microbiome in hepatobiliary health and disease[J].Liver Int,2016,36(4):480-487．
|
|
[15]KEVANS D,TYLER AD,HOLM K,et al.Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis[J].J Crohns Colitis,2016,10(3):330-337．
|
|
[16]SABINO J,VIEIRA-SILVA S,MACHIELS K,et al.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J].Gut,2016,65(10):1681-1689．
|
|
[17]PATEL M,WATSON A,RUSHBROOK S.A mechanistic insight into the role of gut microbiota in the pathogenesis of primary sclerosing cholangitis[J].Gastroenterology,2019,157(6):1686-1688．
|
|
[18]LIAO L,SCHNEIDER KM,GALVEZ E,et al.Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis[J].Gut,2019,68(8):1477-1492．
|
|
[19]BOONSTRA K,de VRIES EM,van GELOVEN N,et al.Risk factors for primary sclerosing cholangitis[J].Liver Int,2016,36(1):84-91．
|
|
[20]ANDERSEN IM,TENGESDAL G,LIE BA,et al.Effects of coffee consumption,smoking,and hormones on risk for primary sclerosing cholangitis[J].Clin Gastroenterol Hepatol,2014,12(6):1019-1028．
|
|
[21]GATSELIS NK,ZACHOU K,KOUKOULIS GK,et al.Autoimmune hepatitis,one disease with many faces:Etiopathogenetic,clinico-laboratory and histological characteristics[J].World J Gastroenterol,2015,21(1):60-83．
|
|
[22]GRNBK L,VILSTRUP H,JEPSEN P.Autoimmune hepatitis in denmark:Incidence,prevalence,prognosis,and causes of death.Anationwide registry-based cohort study[J].J Hepatol,2014,60(3):612-617．
|
|
[23]PENG M,LI Y,ZHANG M,et al.Clinical features in different age groups of patients with autoimmune hepatitis[J].Exp Ther Med,2014,7(1):145-148．
|
|
[24]de BOER YS,van GERVEN NM,ZWIERS A,et al.Genome-wide association study identifies variants associated with autoimmune hepatitis type 1[J].Gastroenterology,2014,147(2):443-452.e5．
|
|
[25]van GERVEN NM,de BOER YS,ZWIERS A,et al.HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1[J].Genes Immun,2015,16(4):247-252．
|
|
[26]BITTENCOURT PL,GOLDBERG AC,CANADO EL,et al.Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2[J].Am J Gastroenterol,1999,94(7):1906-1913．
|
|
[27]CZAJA AJ,CARPENTER HA,MOORE SB.HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients[J].Dig Dis Sci,2008,53(2):522-528．
|
|
[28]FERRI S,LONGHI MS,DE MOLO C,et al.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis[J].Hepatology,2010,52(3):999-1007．
|
|
[29]LONGHI MS,MEDA F,WANG P,et al.Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis[J].Hepatology,2008,47(2):581-591．
|
|
[30]LIANG M,LIWEN Z,YUN Z,et al.The Imbalance between FOXP3+TREGS and Th1/Th17/Th22 Cells in patients with newly diagnosed autoimmune hepatitis[J].J Immunol Res,2018,2018:3753081．
|
|
[31]LIU Y,YAN W,YUAN W,et al.Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis[J].Clin Immunol,2019,198:79-88．
|
|
[32]OO YH,WESTON CJ,LALOR PF,et al.Distinct roles for CCR4and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver[J].J Immunol,2010,184(6):2886-2898．
|
|
[33]ZHANG X,XIAO X,LAN P,et al.OX40 co-stimulation inhibits Foxp3 expression and treg induction via BATF3-dependent and independent mechanisms[J].Cell Rep,2018,24(3):607-618．
|
|
[34]LEI W,ZENG DX,ZHU CH,et al.The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma[J].J Thorac Dis,2014,6(7):979-987．
|
|
[35]STURGEON C,FASANO A.Zonulin,a regulator of epithelial and endothelial barrier functions,and its involvement in chronic inflammatory diseases[J].Tissue Barriers,2016,4(4):e1251384．
|
|
[36]CANFORA EE,JOCKEN JW,BLAAK EE.Short-chain fatty acids in control of body weight and insulin sensitivity[J].Nat Rev Endocrinol,2015,11(10):577-591．
|
|
[37]DEN BESTEN G,van EUNEN K,GROEN AK,et al.The role of short-chain fatty acids in the interplay between diet,gut microbiota,and host energy metabolism[J].J Lipid Res,2013,54(9):2325-2340．
|
|
[38]SHENG L,JENA PK,HU Y,et al.Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation[J].J Pathol,2017,243(4):431-441．
|
|
[39]FLOREANI A,RESTREPO-JIMNEZ P,SECCHI MF,et al.Etiopathogenesis of autoimmune hepatitis[J].J Autoimmun,2018,95:133-143．
|
|
[40]MA WT,CHEN DK.Immunological abnormalities in patients with primary biliary cholangitis[J].Clin Sci(Lond),2019,133(6):741-760．
|
|
[41]JOSHITA S,UMEMURA T,TANAKA E,et al.Genetics and epigenetics in the pathogenesis of primary biliary cholangitis[J].Clin JGastroenterol,2018,11(1):11-18．
|
|
[42]TANAKA A,LEUNG P,GERSHWIN ME.The genetics of primary biliary cholangitis[J].Curr Opin Gastroenterol,2019,35(2):93-98．
|
|
[43]DARLAY R,AYERS KL,MELLS GF,et al.Amino acid residues in five separate HLA genes can explain most of the known associations between the MHC and primary biliary cholangitis[J].PLo S Genet,2018,14(12):e1007833．
|
|
[44] QIU F,TANG R,ZUO X,et al.A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J].Nat Commun,2017,8:14828．
|
|
[45]LAZARIDIS KN,TALWALKAR JA.Clinical epidemiology of primary biliary cirrhosis:Incidence,prevalence,and impact of therapy[J].JClin Gastroenterol,2007,41(5):494-500．
|
|
[46]YANG GX,LIAN ZX,CHUANG YH,et al.Adoptive transfer of CD8(+)T cells from transforming growth factor beta receptor type II(dominant negative form)induces autoimmune cholangitis in mice[J].Hepatology,2008,47(6):1974-1982．
|
|
[47]BERNUZZI F,FENOGLIO D,BATTAGLIA F,et al.Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis[J].J Autoimmun,2010,35(3):176-180．
|
|
[48]LAN RY,CHENG C,LIAN ZX,et al.Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis[J].Hepatology,2006,43(4):729-737．
|
|
[49]LIASKOU E,PATEL SR,WEBB G,et al.Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γsecreting cells[J].J Autoimmun,2018,94:143-155．
|
|
[50]DAVIES YK,COX KM,ABDULLAH BA,et al.Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin:An immunomodulating antibiotic[J].J Pediatr Gastroenterol Nutr,2008,47(1):61-67．
|
|
[51]YANG CY,MA X,TSUNEYAMA K,et al.IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis:Implications for therapy[J].Hepatology,2014,59(5):1944-1953．
|
|
[52]SONG Y,YANG H,JIANG K,et al.miR-181a regulates Th17 cells distribution via up-regulated BCL-2 in primary biliary cholangitis[J].Int Immunopharmacol,2018,64:386-393．
|
|
[53]YAO Y.Roles of henatopoietic system,cytokines and intestinal bacteria in the pathogeny of murine primary biliary cirrhosis[D].Hefei:U-niversity of Science and Technology of China,2015.(in Chinese)姚远．原发性胆汁性肝硬化模型鼠发病过程中造血系统、细胞因子、肠道菌群的作用探究[D]．合肥:中国科学技术大学，2015．
|
|
[54]LV LX,FANG DQ,SHI D,et al.Alterations and correlations of the gut microbiome,metabolism and immunity in patients with primary biliary cirrhosis[J].Environ Microbiol,2016,18(7):2272-2286．
|
|
[55]HIRAMATSU K,HARADA K,TSUNEYAMA K,et al.Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis[J].JHepatol,2000,33(1):9-18．
|
|
[56]OTA M,KATSUYAMA Y,HAMANO H,et al.Two critical genes(HLA-DRB1 and ABCF1)in the HLA region are associated with the susceptibility to autoimmune pancreatitis[J].Immunogenetics,2007,59(1):45-52．
|
|
[57]PARK DH,KIM MH,OH HB,et al.Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis[J].Gastroenterology,2008,134(2):440-446．
|
|
[58]WATANABE T,YAMASHITA K,FUJIKAWA S,et al.Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced Ig G4 responses in autoimmune pancreatitis[J].Arthritis Rheum,2012,64(3):914-924．
|
|
[59]MAEHARA T,MORIYAMA M,NAKASHIMA H,et al.Interleukin-21 contributes to germinal centre formation and immunoglobulin G4production in Ig G4-related dacryoadenitis and sialoadenitis,socalled Mikulicz's disease[J].Ann Rheum Dis,2012,71(12):2011-2019．
|
|
[60]LIAN M,WANG Q,JIANG X,et al.The immunobiology of receptor activator for nuclear factor kappa B ligand and myeloid-derived suppressor cell activation in immunoglobulin G4-related sclerosing cholangitis[J].Hepatology,2018,68(5):1922-1936．
|
|
[61]HARADA K,HSU M,IKEDA H,et al.Application and validation of a new histologic staging and grading system for primary biliary cirrhosis[J].J Clin Gastroenterol,2013,47(2):174-181．
|
|
[62]SINGAL AK,STANCA CM,CLARK V,et al.Natural history of small duct primary sclerosing cholangitis:A case series with review of the literature[J].Hepatol Int,2011,5(3):808-813．
|
|
[63]ZHANG S,LUO J,LI J,et al.Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease:2-year clinical experience[J].Clin Chem Lab Med,2017,55(6):865-875．
|
|
[64]CHEN YT,SU JS,TSENG CW,et al.Inflammatory bowel disease on the risk of acute pancreatitis:A population-based cohort study[J].J Gastroenterol Hepatol,2016,31(4):782-787．
|
|
[65]PEZZILLI R,PAGANO N.Benign exocrine pancreatic diseases in inflammatory bowel diseases[J].Dig Dis,2017,35(5):449-453．
|
|
[66]TSEN A,ALISHAHI Y,ROSENKRANZ L.Autoimmune pancreatitis and inflammatory bowel disease:An updated review[J].J Clin Gastroenterol,2017,51(3):208-214．
|
|
[67]KU Y,HONG SM,FUJIKURA K,et al.IL-8 expression in granulocytic epithelial lesions of idiopathic duct-centric pancreatitis(type2 autoimmune pancreatitis)[J].Am J Surg Pathol,2017,41(8):1129-1138.
|
DownLoad: